Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q3 2019 · 10-Q
Revenue$285.91M$285.91Mno prior Q3 2018 on file Net Income$226.09M$226.09Mno prior Q3 2018 on file EPS Diluted$1.95$1.95no prior Q3 2018 on file Operating Income$224,676,000— Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$190,698,000— Margins · derivedOperating margin78.6%
Net margin79.1%
ended Sep 30, 2019 · filed Nov 7, 2019 · 38 d after period end